Endothelial cells in aging arterial walls accumulate senescent phenotypes (p16+, p21+, SA-β-Gal+) at 15–30x higher frequency than young arteries. These senescent endothelial cells reduce nitric oxide production, increase endothelial permeability, promote inflammatory cell recruitment, and drive intimal thickening — core mechanisms of age-related cardiovascular disease.

Can senolytics reduce arterial age?

"Arterial age" measured by pulse wave velocity shows improvements in animal models post-senolytic treatment. Human arterial aging data from senolytics is limited to indirect biomarkers (IL-6, ICAM-1). Direct arterial stiffness measurements in human senolytic trials are ongoing.

Should people with heart disease use senolytics?

Established cardiovascular disease patients are in principle excellent candidates for senolytics (high endothelial senescent cell burden). However, dasatinib carries cardiac considerations (QTc) that require physician evaluation. Natural senolytics (fisetin, quercetin) have favorable cardiovascular safety profiles.